Literature DB >> 8643455

Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases.

Z X Xiao1, D Ginsberg, M Ewen, D M Livingston.   

Abstract

p107 is a retinoblastoma protein-related phosphoprotein that, when overproduced, displays a growth inhibitory function. It interacts with and modulates the activity of the transcription factor, E2F-4. In addition, p107 physically associates with cyclin E-CDK2 and cyclin A-CDK2 complexes in late G1 and at G1/S, respectively, an indication that cyclin-dependent kinase complexes may regulate, contribute to, and/or benefit from p107 function during the cell cycle. Our results show that p107 phosphorylation begins in mid G1 and proceeds through late G1 and S and that cyclin D-associated kinase(s) contributes to this process. In addition, E2F-4 binds selectively to hypophosphorylated p107, and G1 cyclin-dependent p107 phosphorylation leads to the dissociation of p107-E2F-4 complexes as well as inactivation of p107 G1 blocking function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643455      PMCID: PMC39330          DOI: 10.1073/pnas.93.10.4633

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Identification of a growth suppression domain within the retinoblastoma gene product.

Authors:  X Q Qin; T Chittenden; D M Livingston; W G Kaelin
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

2.  Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products.

Authors:  E Harlow; B R Franza; C Schley
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

3.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

4.  Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1.

Authors:  N Dyson; M Dembski; A Fattaey; C Ngwu; M Ewen; K Helin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

6.  Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain.

Authors:  X Mayol; X Graña; A Baldi; N Sang; Q Hu; A Giordano
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

7.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins.

Authors:  M E Ewen; H K Sluss; C J Sherr; H Matsushime; J Kato; D M Livingston
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

8.  Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.

Authors:  E Lees; B Faha; V Dulic; S I Reed; E Harlow
Journal:  Genes Dev       Date:  1992-10       Impact factor: 11.361

9.  Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130.

Authors:  X Mayol; J Garriga; X Graña
Journal:  Oncogene       Date:  1995-08-17       Impact factor: 9.867

10.  A- and B-type cyclins differentially modulate substrate specificity of cyclin-cdk complexes.

Authors:  D S Peeper; L L Parker; M E Ewen; M Toebes; F L Hall; M Xu; A Zantema; A J van der Eb; H Piwnica-Worms
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  40 in total

1.  Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression.

Authors:  X Chen; R Prywes
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

2.  E1A blocks hyperphosphorylation of p130 and p107 without affecting the phosphorylation status of the retinoblastoma protein.

Authors:  M Parreño; J Garriga; A Limón; X Mayol; G R Beck; E Moran; X Graña
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  Loss of p19(ARF) eliminates the requirement for the pRB-binding motif in simian virus 40 large T antigen-mediated transformation.

Authors:  H H Chao; A M Buchmann; J A DeCaprio
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Exploring the functional complexity of cellular proteins by protein knockout.

Authors:  Jianxuan Zhang; Ning Zheng; Pengbo Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

6.  Interactions between human cytomegalovirus IE1-72 and cellular p107: functional domains and mechanisms of up-regulation of cyclin E/cdk2 kinase activity.

Authors:  Zhigang Zhang; Shu-Mei Huong; Xin Wang; David Y Huang; Eng-Shang Huang
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation.

Authors:  Yuxia Zhang; Ping Xu; Kyungtae Park; Yunhee Choi; David D Moore; Li Wang
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

8.  Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism.

Authors:  Anton Chestukhin; Larisa Litovchick; Katherine Rudich; James A DeCaprio
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

9.  Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Andrew Burgess; Andrew J Deans; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

10.  Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells.

Authors:  Tiziana Parisi; Andreas R Beck; Nathalie Rougier; Tom McNeil; Linda Lucian; Zena Werb; Bruno Amati
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.